EBM Newsletter – Evidence-based Medicine
ALERT Evidence Medicine !
Evidence-based Medicine
PCI: compared with a Heparin-based regimen, a Bivalirudin-based regimen increases the risk of myocardial infarction and stent thrombosis, but decreases the risk of bleeding
Bivalirudin is an alternative to Heparin in patients undergoing percutaneous coronary intervention ( PCI ). A meta-analysis of randomised controlled trials was performed to define the effects of a Bi …
Acute gout: low-dose may be the preferred treatment option than high-dose Colchicine
This is an update of a Cochrane review first published in 2006. Gout is one of the most common rheumatic diseases worldwide. Despite the use of Colchicine as one of the first-line therapies for the tr …
Patent foramen ovale closure with Amplatzer appears superior to medical therapy in preventing strokes in patients with cryptogenic embolism
Up to 40% of ischaemic strokes are cryptogenic. A strong association between cryptogenic stroke and the prevalence of patent foramen ovale ( PFO ) suggests paradoxical embolism via PFO as a potential …
Per iscriversi alla Newsletter Evidence Medicine in inglese
–
Link: www.xagenaweb.it Coloro che sono già iscritti possono accedere al Pannello di Controllo inserendo l’indirizzo e-mail con il quale ricevono le Newsletter e la Password personale [ RIPORTATA IN FONDO A OGNI NEWSLETTER ] E’ importante confermare la modifica cliccando sul tasto SALVA MODIFICA
